You are currently reviewing an older revision of this page.
Exocrine Pancreatic insufficiency (EPI) Treatment Study
Aran Mas DVM MRCVS
P-J.M.Noble BSc BVM&S PhD MRCVS,
A.J.German BVSc PhD CertSAM DipECVIM-CA MRCVS
EPI is a common condition in dogs with early response to therapy being critical for positive outcomes (Batchelor et al, 2007). Pancreatic enzyme supplementation is the key component of therapy in EPI. Numerous enzyme preparations exist for use in dogs, some of which are enteric-coated and some uncoated. Although one retrospective study on treatment of EPI suggested a better response with uncoated preparations (Hall et al., 1991), there was no difference in response amongst preparations in a more recent study (Batchelor et al., 2007). However, prospective clinical trials, on treatment of EPI, are lacking.
The Small Animal Teaching Hospital, University of Liverpool, is performing the first randomised double-blind trial to examine the effect of enteric coating on efficacy of pancreatic enzyme supplementation in the treatment of canine EPI. We are aiming to recruit dogs recently diagnosed with EPI for inclusion in this trial. Enrolled patients will undergo clinical evaluation, two months of treatment and follow-up advice, all free of charge.
Inclusion criteria:
Exclusion criteria:
If you have a suitable case and would like to discuss enrolment on the trial, please do not hesitate to contact us (telephone 0151 795 6100, vetinmed@liv.ac.uk)
References
BATCHELOR, D.J., NOBLE, P.J.M., CRIPPS, P.J., TAYLOR R., GERMAN, A.J. (2007) Prognostic factors in canine exocrine pancreatic insufficiency: prolonged survival is likely if clinical remission is achieved. Journal of Veterinary Internal Medicine 21; 54-60
HALL, E.J., BOND, P.M., MCLEAN, C., BATT, RM, MCLEAN, L (1991) A survey of the diagnosis and treatment of canine exocrine pancreatic insufficiency. Journal of Small Animal Practice 32; 613–619.